FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567146430> ?p ?o ?g. }

• W1567146430 endingPage "21S" @default.
• W1567146430 startingPage "3914S" @default.
• W1567146430 abstract "The aim of the study was to establish and refine a preclinical model to alpha-immunoradiotherapy of ovarian cancer.At-211 was produced by cyclotron irradiation of a bismuth-209 target and isolated using a novel dry distillation procedure. Monoclonal antibodies were radiohalogenated with the intermediate reagent N-succinimidyl 3-(trimethylstannyl)benzoate and characterized in terms of radiochemical yield and in vitro binding properties. In vitro OVCAR-3 cells were irradiated using an external Cobalt-60 beam, as reference, or At-211-albumin and labeled antibody. Growth assays were used to establish cell survival. A Monte Carlo program was developed to simulate the energy imparted and the track length distribution. Nude mice were used for studies of WBC depression, with various activities of Tc-99m antibodies, as reference, and At-211 antibodies. In efficacy studies, OVCAR-3 cells were inoculated i.p., and animals were treated 2 weeks later. The animals were either dissected 6 weeks later or followed-up for long-term survival.A rapid distillation procedure, as well as a rapid and high-yield, single-pot labeling procedure, was achieved. From growth inhibition data, the relative biological effectiveness of the alpha-emission for OVCAR-3 cells was estimated to be approximately 5, which is in the same range as found in vivo for hematological toxicity. At-211 MOv18 was found to effectively inhibit the development of tumors and ascites, also resulting in long-term survival without significant toxic effect.Use of the short-range, high-linear energy transfer alpha-emitter At-211 conjugated to a surface epitope-recognizing monoclonal antibody appears to be highly efficient without significant toxicity in a mouse peritoneal tumor model, urging a Phase I clinical trial." @default.
• W1567146430 created "2016-06-24" @default.
• W1567146430 creator A5008520517 @default.
• W1567146430 creator A5020125841 @default.
• W1567146430 creator A5025599550 @default.
• W1567146430 creator A5033194381 @default.
• W1567146430 creator A5034871404 @default.
• W1567146430 creator A5035448306 @default.
• W1567146430 creator A5046800369 @default.
• W1567146430 creator A5060561121 @default.
• W1567146430 creator A5073464691 @default.
• W1567146430 date "2003-09-01" @default.
• W1567146430 modified "2023-09-27" @default.
• W1567146430 title "Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model." @default.
• W1567146430 cites W145280565 @default.
• W1567146430 cites W1647609745 @default.
• W1567146430 cites W1831034898 @default.
• W1567146430 cites W1941252725 @default.
• W1567146430 cites W1944633059 @default.
• W1567146430 cites W1972284839 @default.
• W1567146430 cites W1978446954 @default.
• W1567146430 cites W1988368614 @default.
• W1567146430 cites W2031619819 @default.
• W1567146430 cites W2031822911 @default.
• W1567146430 cites W2036342934 @default.
• W1567146430 cites W2036742887 @default.
• W1567146430 cites W2037134305 @default.
• W1567146430 cites W2046741585 @default.
• W1567146430 cites W2058426435 @default.
• W1567146430 cites W2060726255 @default.
• W1567146430 cites W2064525881 @default.
• W1567146430 cites W2066618419 @default.
• W1567146430 cites W2068148709 @default.
• W1567146430 cites W2076046691 @default.
• W1567146430 cites W2078261279 @default.
• W1567146430 cites W2107579697 @default.
• W1567146430 cites W2112263989 @default.
• W1567146430 cites W2128967036 @default.
• W1567146430 cites W2149180485 @default.
• W1567146430 cites W2151230949 @default.
• W1567146430 cites W2161227498 @default.
• W1567146430 cites W2171140185 @default.
• W1567146430 cites W2213133654 @default.
• W1567146430 cites W2406806003 @default.
• W1567146430 cites W2471843034 @default.
• W1567146430 cites W2419017482 @default.
• W1567146430 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14506189" @default.
• W1567146430 hasPublicationYear "2003" @default.
• W1567146430 type Work @default.
• W1567146430 sameAs 1567146430 @default.
• W1567146430 citedByCount "21" @default.
• W1567146430 countsByYear W15671464302012 @default.
• W1567146430 countsByYear W15671464302013 @default.
• W1567146430 countsByYear W15671464302014 @default.
• W1567146430 countsByYear W15671464302015 @default.
• W1567146430 countsByYear W15671464302019 @default.
• W1567146430 countsByYear W15671464302023 @default.
• W1567146430 crossrefType "journal-article" @default.
• W1567146430 hasAuthorship W1567146430A5008520517 @default.
• W1567146430 hasAuthorship W1567146430A5020125841 @default.
• W1567146430 hasAuthorship W1567146430A5025599550 @default.
• W1567146430 hasAuthorship W1567146430A5033194381 @default.
• W1567146430 hasAuthorship W1567146430A5034871404 @default.
• W1567146430 hasAuthorship W1567146430A5035448306 @default.
• W1567146430 hasAuthorship W1567146430A5046800369 @default.
• W1567146430 hasAuthorship W1567146430A5060561121 @default.
• W1567146430 hasAuthorship W1567146430A5073464691 @default.
• W1567146430 hasConcept C121608353 @default.
• W1567146430 hasConcept C126322002 @default.
• W1567146430 hasConcept C150903083 @default.
• W1567146430 hasConcept C159654299 @default.
• W1567146430 hasConcept C185592680 @default.
• W1567146430 hasConcept C202751555 @default.
• W1567146430 hasConcept C203014093 @default.
• W1567146430 hasConcept C207001950 @default.
• W1567146430 hasConcept C2776146153 @default.
• W1567146430 hasConcept C2780427987 @default.
• W1567146430 hasConcept C502942594 @default.
• W1567146430 hasConcept C542903549 @default.
• W1567146430 hasConcept C55493867 @default.
• W1567146430 hasConcept C71924100 @default.
• W1567146430 hasConcept C86803240 @default.
• W1567146430 hasConceptScore W1567146430C121608353 @default.
• W1567146430 hasConceptScore W1567146430C126322002 @default.
• W1567146430 hasConceptScore W1567146430C150903083 @default.
• W1567146430 hasConceptScore W1567146430C159654299 @default.
• W1567146430 hasConceptScore W1567146430C185592680 @default.
• W1567146430 hasConceptScore W1567146430C202751555 @default.
• W1567146430 hasConceptScore W1567146430C203014093 @default.
• W1567146430 hasConceptScore W1567146430C207001950 @default.
• W1567146430 hasConceptScore W1567146430C2776146153 @default.
• W1567146430 hasConceptScore W1567146430C2780427987 @default.
• W1567146430 hasConceptScore W1567146430C502942594 @default.
• W1567146430 hasConceptScore W1567146430C542903549 @default.
• W1567146430 hasConceptScore W1567146430C55493867 @default.
• W1567146430 hasConceptScore W1567146430C71924100 @default.
• W1567146430 hasConceptScore W1567146430C86803240 @default.
• W1567146430 hasIssue "10 Pt 2" @default.

• next